Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries

Abstract Background There have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatitis testing guidance and in particular the feasibility of proposed recom...

Full description

Bibliographic Details
Main Authors: Azumi Ishizaki, Julie Bouscaillou, Niklas Luhmann, Stephanie Liu, Raissa Chua, Nick Walsh, Sarah Hess, Elena Ivanova, Teri Roberts, Philippa Easterbrook
Format: Article
Language:English
Published: BMC 2017-11-01
Series:BMC Infectious Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12879-017-2767-0
_version_ 1819069594781876224
author Azumi Ishizaki
Julie Bouscaillou
Niklas Luhmann
Stephanie Liu
Raissa Chua
Nick Walsh
Sarah Hess
Elena Ivanova
Teri Roberts
Philippa Easterbrook
author_facet Azumi Ishizaki
Julie Bouscaillou
Niklas Luhmann
Stephanie Liu
Raissa Chua
Nick Walsh
Sarah Hess
Elena Ivanova
Teri Roberts
Philippa Easterbrook
author_sort Azumi Ishizaki
collection DOAJ
description Abstract Background There have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatitis testing guidance and in particular the feasibility of proposed recommendations, we undertook a survey across a range of organisations engaged with hepatitis testing in low- and middle-income countries (LMICs). Our objective was to describe current hepatitis B and C testing practices across a range of settings in different countries, as well as key barriers or challenges encountered and proposed solutions to promote testing scale-up. Methods Hepatitis testing programmes in predominantly LMICs were identified from the WHO Global Hepatitis Programme contacts database and through WHO regional offices, and invited to participate. The survey comprised a six-part structured questionnaire: general programme information, description of hepatitis testing, treatment and care services, budget and funding, data on programme outcomes, and perceptions on key barriers encountered and strategies to address these. Results We interviewed 22 viral hepatitis testing programmes from 19 different countries. Nine were from the African region; 6 from the Western Pacific; 4 from South-East Asia; and 3 from Eastern Europe. All but four of the programmes were based in LMICs, and 10 (45.5%) were supported by non-governmental or international organizations. All but two programmes undertook targeted testing of specific affected populations such as people living with HIV, people who inject drugs, sex workers, health care workers, and pregnant women. Only two programmes focussed on routine testing in the general population. The majority of programmes were testing in hospital-based or other health facilities, particularly HIV clinics, and community-based testing was limited. Nucleic acid testing (NAT) for confirmation of HCV and HBV viraemia was available in only 30% and 18% of programmes, respectively. Around a third of programmes required some patient co-payment for diagnosis. The most commonly identified challenges in scale-up of hepatitis testing were: limited community awareness about viral hepatitis; lack of facilities or services for hepatitis testing; no access to low cost treatment, particularly for HCV; absence of national guidance and policies; no dedicated budget for hepatitis; and lack of trained health care and laboratory workers. Conclusions At this early stage in the global scale-up of testing for viral hepatitis, there is a wide variation in testing practices and approaches across different programmes. There remains limited access to NAT to confirm viraemia, and patient self-payment for testing and treatment is common. There was consensus from implementing organizations that scale-up of testing will require increased community awareness, health care worker training, development of national strategies and guidelines, and improved access to low cost NAT virological testing.
first_indexed 2024-12-21T16:52:32Z
format Article
id doaj.art-593b71afe77048d8bcdff5c5fabf1252
institution Directory Open Access Journal
issn 1471-2334
language English
last_indexed 2024-12-21T16:52:32Z
publishDate 2017-11-01
publisher BMC
record_format Article
series BMC Infectious Diseases
spelling doaj.art-593b71afe77048d8bcdff5c5fabf12522022-12-21T18:56:50ZengBMCBMC Infectious Diseases1471-23342017-11-0117S112914010.1186/s12879-017-2767-0Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countriesAzumi Ishizaki0Julie Bouscaillou1Niklas Luhmann2Stephanie Liu3Raissa Chua4Nick Walsh5Sarah Hess6Elena Ivanova7Teri Roberts8Philippa Easterbrook9Global Hepatitis Programme, World Health OrganizationMédecins du MondeMédecins du MondeWorld Health Organization, Regional Office of the Western PacificWorld Health Organization, Regional Office of the Western PacificWorld Health Organization, Regional Office of the Western PacificGlobal Hepatitis Programme, World Health OrganizationFoundation for Innovative New DiagnosticsFoundation for Innovative New DiagnosticsGlobal Hepatitis Programme, World Health OrganizationAbstract Background There have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatitis testing guidance and in particular the feasibility of proposed recommendations, we undertook a survey across a range of organisations engaged with hepatitis testing in low- and middle-income countries (LMICs). Our objective was to describe current hepatitis B and C testing practices across a range of settings in different countries, as well as key barriers or challenges encountered and proposed solutions to promote testing scale-up. Methods Hepatitis testing programmes in predominantly LMICs were identified from the WHO Global Hepatitis Programme contacts database and through WHO regional offices, and invited to participate. The survey comprised a six-part structured questionnaire: general programme information, description of hepatitis testing, treatment and care services, budget and funding, data on programme outcomes, and perceptions on key barriers encountered and strategies to address these. Results We interviewed 22 viral hepatitis testing programmes from 19 different countries. Nine were from the African region; 6 from the Western Pacific; 4 from South-East Asia; and 3 from Eastern Europe. All but four of the programmes were based in LMICs, and 10 (45.5%) were supported by non-governmental or international organizations. All but two programmes undertook targeted testing of specific affected populations such as people living with HIV, people who inject drugs, sex workers, health care workers, and pregnant women. Only two programmes focussed on routine testing in the general population. The majority of programmes were testing in hospital-based or other health facilities, particularly HIV clinics, and community-based testing was limited. Nucleic acid testing (NAT) for confirmation of HCV and HBV viraemia was available in only 30% and 18% of programmes, respectively. Around a third of programmes required some patient co-payment for diagnosis. The most commonly identified challenges in scale-up of hepatitis testing were: limited community awareness about viral hepatitis; lack of facilities or services for hepatitis testing; no access to low cost treatment, particularly for HCV; absence of national guidance and policies; no dedicated budget for hepatitis; and lack of trained health care and laboratory workers. Conclusions At this early stage in the global scale-up of testing for viral hepatitis, there is a wide variation in testing practices and approaches across different programmes. There remains limited access to NAT to confirm viraemia, and patient self-payment for testing and treatment is common. There was consensus from implementing organizations that scale-up of testing will require increased community awareness, health care worker training, development of national strategies and guidelines, and improved access to low cost NAT virological testing.http://link.springer.com/article/10.1186/s12879-017-2767-0Hepatitis testingWHO guidelines on hepatitis B and C testingProgramme experienceFeasibilityLow- and middle-income countries
spellingShingle Azumi Ishizaki
Julie Bouscaillou
Niklas Luhmann
Stephanie Liu
Raissa Chua
Nick Walsh
Sarah Hess
Elena Ivanova
Teri Roberts
Philippa Easterbrook
Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries
BMC Infectious Diseases
Hepatitis testing
WHO guidelines on hepatitis B and C testing
Programme experience
Feasibility
Low- and middle-income countries
title Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries
title_full Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries
title_fullStr Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries
title_full_unstemmed Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries
title_short Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries
title_sort survey of programmatic experiences and challenges in delivery of hepatitis b and c testing in low and middle income countries
topic Hepatitis testing
WHO guidelines on hepatitis B and C testing
Programme experience
Feasibility
Low- and middle-income countries
url http://link.springer.com/article/10.1186/s12879-017-2767-0
work_keys_str_mv AT azumiishizaki surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT juliebouscaillou surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT niklasluhmann surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT stephanieliu surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT raissachua surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT nickwalsh surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT sarahhess surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT elenaivanova surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT teriroberts surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries
AT philippaeasterbrook surveyofprogrammaticexperiencesandchallengesindeliveryofhepatitisbandctestinginlowandmiddleincomecountries